Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting

Phase 3

UbrogepantStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Sponsor:

AbbVie

Code:

NCT06417775

Conditions

Migraine

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ubrogepant

Placebo for Ubrogepant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by AbbVie on 2025-11-12.